debrisoquin has been researched along with Behavior Disorders in 6 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Other reported effects are toxic confusional states and psychotic reactions." | 2.36 | Psychiatric side effects of antihypertensive drugs other than reserpine. ( Fleminger, R; Paykel, ES; Watson, JP, 1982) |
| "Debrisoquine MR was correlated with the dose of haloperidol (r = 0." | 1.32 | Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. ( Berecz, R; de la Rubia, A; Dorado, P; LLerena, A, 2004) |
| " One must consider the effects of thioridazine dosage on CYP2D6, because it may influence the metabolism of concomitant drugs or produce clinically important adverse effects such as cardiotoxicity." | 1.31 | Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. ( Berecz, R; de la Rubia, A; Dorado, P; Fernández-Salguero, P; LLerena, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Llerena, A | 5 |
| Dorado, P | 4 |
| Peñas-Lledó, EM | 2 |
| de la Rubia, A | 3 |
| Berecz, R | 3 |
| Paykel, ES | 1 |
| Fleminger, R | 1 |
| Watson, JP | 1 |
| Fernández-Salguero, P | 1 |
| Benítez, J | 1 |
| Piñas, B | 1 |
| García, MA | 1 |
| Martínez, C | 1 |
| Cobaleda, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for debrisoquin and Behavior Disorders
| Article | Year |
|---|---|
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Topics: Antipsychotic Agents; Biomarkers; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debri | 2009 |
Psychiatric side effects of antihypertensive drugs other than reserpine.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Anxiety; Bethanidine; Clonidine; Debrisoquin; | 1982 |
1 trial available for debrisoquin and Behavior Disorders
| Article | Year |
|---|---|
No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
Topics: Alleles; Antipsychotic Agents; Cytochrome P-450 CYP1A2; Debrisoquin; Dose-Response Relationship, Dru | 2007 |
3 other studies available for debrisoquin and Behavior Disorders
| Article | Year |
|---|---|
Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 C | 2004 |
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2 | 2001 |
Debrisoquine oxidation phenotype in psychiatric patients.
Topics: Adult; Aged; Debrisoquin; Female; Humans; Isoquinolines; Male; Mental Disorders; Middle Aged; Oxidat | 1989 |